SCHEMBL3551718

SCHEMBL3551718

c1cncc(CN2CCC[N]CC2)c1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.76
CHRNA4 P43681 1/20 0.76
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 3/20 0.51
TDP1 Q9NUW8 1/20 0.51
CASP1 P29466 1/20 0.51
CASP4 P49662 1/20 0.51
CASP5 P51878 1/20 0.51
TRPV6 Q9H1D0 4/20 0.50
DRD2 P14416 1/20 0.49
DRD4 P21917 1/20 0.49
DRD3 P35462 1/20 0.49
GFER P55789 1/20 0.47
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1365626 0.94 CHRNB2 (0.74) CHRNB2CHRNA4KDM4EALDH1A1TDP1
N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL30341021 0.87 CHRNB2 (1.00) CHRNB2CHRNA4KDM4EALDH1A1TDP1
N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL1538320 0.87 CHRNB2 (1.00) CHRNB2CHRNA4KDM4EALDH1A1TDP1
SCHEMBL30711590 0.87 CHRNB2 (0.93) CHRNB2CHRNA4KDM4EALDH1A1TDP1
SCHEMBL5166215 0.85 CHRNB2 (0.96) CHRNB2CHRNA4KDM4EALDH1A1TDP1
N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL27432542 0.85 CHRNB2 (0.96) CHRNB2CHRNA4KDM4EALDH1A1TDP1
Bromide SCHEMBL28127803 0.85 CHRNB2 (0.89) CHRNB2CHRNA4KDM4EALDH1A1TDP1
SCHEMBL16026435 0.83 CHRNB2 (0.85) CHRNB2CHRNA4KDM4EALDH1A1TDP1
SCHEMBL30341055 0.82 CHRNB2 (0.83) CHRNB2CHRNA4KDM4EALDH1A1TDP1
SCHEMBL42218 0.82 SIGMAR1 (0.61) CHRNB2CHRNA4ALDH1A1DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834015-B2 treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV skin damage, and as chemosensitizers or radiosensitizers for cancer treatment INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2010-11-16 US disclosed
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209523-A1 Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp) PARP1, PARP2, PARP11 CHRNB2 4534/4885CHRNA4 4647/4885KDM4E 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.